SINGAPORE,
April 23,
2024 /PRNewswire/ -- GenScript, a global leader in
life sciences and biotechnology, successfully hosted an Open Day
event at its Singapore facility on
the 16th of April, welcoming more than 50 representatives from
Singapore. This event provided an
exclusive look into GenScript's state-of-the-art gene and protein
production facility, particularly highlighting the company's
advancements in AI-driven gene and recombinant protein production.
Guests embarked on a guided tour through the facility, witnessing
the precision and efficiency with which GenScript integrates AI
technology to enhance production.
The highlight during the event was the
introduction of GenScript's latest AI innovations, which have been
designed to optimize recombinant protein production and streamline
processes in unprecedented ways. GenScript has introduced GenSmart™
Codon Optimization (Patent Number: WO2020024917A1), a free online
tool designed to enhance gene sequence design for significantly
improved expression in both prokaryotic and mammalian systems,
covering more than 50 host organisms now. This tool employs an
innovative algorithm inspired by Population Immune Algorithm,
blending concepts from population genetics and immunology. It
examines over 200 gene expression factors, such as GC content,
codon usage, RNase splicing sites, and mRNA destabilizing motifs.
The tool customizes each gene optimization to boost the odds of
producing a functional, active protein. Compared to similar tools
in the market, GenSmart™ Codon Optimization is more accessible and
user-friendly and the yield of the protein expressed via GenSmart™
is up to 10x higher.
GenScript is also utilizing AI to develop other
tools to accelerate enzyme and antibody discovery: The enzyme
engineering platform - Al-deZyme, is designed to accelerate
enzyme evolution via stability and activity optimization. The
antibody AI platform will be able to support in-silicon
developability assessment & optimization of antibody. The use
of artificial intelligence marks a significant leap forward in
GenScript's commitment to providing the fastest and most reliable
services to the life science community, enabling them to conquer
the challenges associated with recombinant antibody expression and
accelerate drug discovery process.
"Today, we stand at the cusp of a new era in
biotechnology," said Dr. Janice Jin,
President at GenScript Asia Pacific. "The convergence of AI with
therapeutic antibody development and drug discovery is not just an
advancement of our capabilities—it's a revolution in how we
approach complex biological challenges. Our Open Day was a showcase
of this synergy and a promise of the collaborative triumphs to
come."
The success of the Open Day marks the start of a
series of collaborative ventures poised to arise from these newly
forged industry relationships. GenScript's commitment to leveraging
AI will continue to drive innovation and success across the life
sciences, with a profound impact anticipated in drug discovery and
beyond.
About GenScript
GenScript Biotech Corporation (HK.1548) is a
world leader in technologies and services for life science R&D
and manufacture. Built upon its solid DNA synthesis technology, the
company comprises four major business units: a life-science
services and products business unit, a biologics contract
development and manufacturing organization (CDMO) business unit, an
industrial synthetic products business unit, and an integrated
global cell therapy company. GenScript accelerates scientific
discovery and therapeutic breakthrough with its customers. Since
its founding in New Jersey, USA in
2002, GenScript has expanded its operations to serve more than
200,000 customers across 100 countries with a dedicated team of
6,900 employees. As of December 31,
2023, 87,700 peer-reviewed journal articles worldwide had
cited GenScript 's services and products. Guided by its mission to
make people and nature healthier through biotechnology, GenScript
strives to become the most trustworthy biotech company in the
world.
For more information, please visit GenScript
Biotech's official website
https://www.genscript.com
CONTACT: Cassie Yap, cassie.yap@genscript.com,
+6531591898
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genscript-singapores-open-day-reveals-pioneering-ai-capabilities-in-recombinant-protein-production-and-drug-discovery-302124775.html
SOURCE GenScript Biotech Corporation